Search Results
Results for: ""
Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025
SAN DIEGO – July 11, 2025 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report second quarter 2025 financial results...
READ MORE →Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 102,350 shares of its common stock and granted an...
READ MORE →Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline
Crinetics announced eight abstracts from its novel clinical development programs will be presented at the Endocrine Society’s Annual Meeting, ENDO...
READ MORE →Patient Focused Drug Development
Stephanie KallayDirector of Patient Advocacy Partners in Progress: How Patient Insights Drive Innovation At Crinetics, our mission has always been...
READ MORE →Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025
Crinetics Pharmaceuticals will host an in-person and virtual R&D Day in New York on Thursday, June 26, 2025, from 9:00...
READ MORE →Crinetics Pharmaceuticals 2025 Annual Meeting of Stockholders
June 11, 2025
READ MORE →Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 74,000 shares of its common stock and granted an...
READ MORE →Crinetics to Participate in the Jefferies Global Healthcare Conference 2025
June 5, 2025
READ MORE →Understanding the Role of IGF-1 in Managing Acromegaly
Dr. Alan KrasnerChief Endocrinologist If you are living with acromegaly, you’ve likely heard your healthcare provider talk about “IGF-1” during...
READ MORE →Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
